Eli Lilly, Justice Reach Agreement in Zyprexa Litigation

Eli Lilly will pay $1.42 billion to resolve civil and criminal charges that it promoted the antipsychotic Zyprexa for off-label uses. Lilly admitted it was guilty of the misdemeanor charge of promoting Zyprexa (olanzapine) to treat dementia in the elderly between September 1999 and March 31, 2001, according to a plea agreement filed in the U.S. District Court for the Eastern District of Pennsylvania. Zyprexa hasn’t been approved for that indication.
Drug Industry Daily